# Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

> **NCT02431312** · PHASE1 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 90 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** INO-1800
- **BIOLOGICAL:** INO-9112
- **DRUG:** Nucleos(t)ide Analogue Treatment

## Key facts

- **NCT ID:** NCT02431312
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-12
- **Primary completion:** 2018-05-22
- **Final completion:** 2018-05-22
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2019-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431312, "Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02431312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*